Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients

被引:3
|
作者
Gardeney, Helene [1 ,2 ]
Bobin, Arthur [1 ,2 ]
Gruchet, Cecile [1 ,2 ]
Sabirou, Florence [1 ,2 ]
Levy, Anthony [1 ,2 ]
Nsiala, Laly [1 ,2 ]
Cailly, Laura [1 ,2 ]
Tomowiak, Cecile [1 ,2 ]
Torregrosa, Jose [1 ,2 ]
Moya, Niels [1 ,2 ]
Hulin, Cyrille [3 ]
Leleu, Xavier [1 ,2 ,4 ]
Guidez, Stephanie [1 ,2 ]
机构
[1] Serv Hematol & Therapie Cellulaire, F-86000 Poitiers, France
[2] INSERM, U1402, CIC, F-86000 Poitiers, France
[3] CHU Bordeaux, Serv Hematol & Therapie Cellulaire, F-33000 Bordeaux, France
[4] Univ Med & Pharm, Serv Hematol & Therapie Cellulaire, F-33000 Poitiers, France
关键词
elderly; multiple myeloma; treatment; frailty; survival; STEM-CELL TRANSPLANTATION; OPEN-LABEL; PLUS POMALIDOMIDE; DEXAMETHASONE; LENALIDOMIDE; DARATUMUMAB; BORTEZOMIB; SURVIVAL; CARFILZOMIB; PREDNISONE;
D O I
10.3390/jcm9113554
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The multiple myeloma (MM) non transplant eligible (NTE) population is growing in line with the aging of the population in Western countries. Historically, this population has been known for having a greater risk of treatment related toxicity, and therefore drug development was slow and rather oriented towards the improvement of safety profile than the optimization of disease control. However, NTE MM patients, at least for the fit/non frail patients in recent years, seemed to have benefited more from a less palliative care to improve the depth of response and then prolong survival. NTE MM being a quite heterogeneous population, there are still a number of groups of patients that are in need of more efficient therapy, avoiding unnecessary toxicity, particularly for the frail patients. The use of triplet regimen with a melphalan-prednisone (MP) backbone has long been the standard of care for NTE MM, often dedicated to non-frail patients. New standards of care, triplet, and even quadruplet combinations, are emerging on the basis of the MP backbone but also on the more recently approved lenalidomide-dexamethasone (Rd) backbone. These developments were largely possible in line with the development of antibody-based immunotherapies (IT) in MM. The objective to improve outcomes with an acceptable safety profile will see other key therapeutic developments such as the dropping of dexamethasone early in the disease course or various attempts to allow permanent treatment discontinuation with a prolonged disease control. In that context, it is possible that immunomonitoring, minimal residual disease (MRD), and genomic risk-adaptation will become key elements of the treatment decisions on triplet-based regimens.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Cerrato, C.
    Oliva, S.
    Petrucci, M. T.
    Caraffa, P.
    Nozzoli, C.
    Finsinger, P.
    Larocca, A.
    De Rosa, L.
    De Paoli, L.
    Montefusco, V.
    Saraci, E.
    Villani, O.
    Carella, A. M.
    Benevolo, G.
    Morabito, F.
    Liberati, A. M.
    Derudas, D.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2014, 99 : 107 - 107
  • [2] Treatment of elderly patients with multiple myeloma
    Boccadoro, M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S11 - S11
  • [3] Treatment of elderly patients with multiple myeloma
    Ludwig, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 26 - 26
  • [4] The treatment of the elderly multiple myeloma patients
    Cavallo, Federica
    Ambrosini, Maria Teresa
    Rus, Cecilia
    Boccadoro, Mario
    Palumbo, Antonio
    LEUKEMIA & LYMPHOMA, 2007, 48 (03) : 469 - 480
  • [5] Treatment for elderly patients with multiple myeloma
    Focosi, Daniele
    LANCET, 2008, 371 (9617): : 983 - 984
  • [6] Treatment for elderly patients with multiple myeloma - Reply
    Facon, Thierry
    Mary, Jean-Yves
    Hulin, Cyrille
    Benboubker, Lotfi
    Attal, Michel
    LANCET, 2008, 371 (9617): : 984 - 985
  • [7] Treatment strategies in elderly patients with multiple myeloma
    Quach, Hang
    Prince, H. Miles
    Mileshkin, Linda
    DRUGS & AGING, 2007, 24 (10) : 829 - 850
  • [8] Frontline Treatment in Elderly Patients With Multiple Myeloma
    Facon, Thierry
    Miguel, Jesus San
    Mateos, Maria Victoria
    Hulin, Cyrille
    SEMINARS IN HEMATOLOGY, 2009, 46 (02) : 133 - 142
  • [9] Frontline treatment of multiple myeloma in elderly patients
    Moreau, Philippe
    Hulin, Cyrille
    Facon, Thierry
    BLOOD REVIEWS, 2008, 22 (06) : 303 - 309
  • [10] EVALUATION OF TREATMENT FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Kabaklic, Amela
    Cernelc, Peter
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2008, 77 : I81 - I86